Dr. Mark Plavsic is Chief Technical Officer at Fate Therapeutics, overseeing the company’s cell therapy manufacturing, supply chain, and technical operations. Dr. Plavsic has more than 20 years of broad experience in process development and end-to-end product development of large scale commercial biologics. Prior to joining Fate Therapeutics, Dr. Plavsic served as Chief Technical Officer at Lysogene, a late stage clinical development gene therapy company with headquarters in Paris, France. Before joining Lysogene, Dr. Plavsic was SVP of CMC at Torque Therapeutics, Inc., and was Head of Product Biosafety at Genzyme/Sanofi, where he was responsible for process improvements and viral safety of all commercial biological products and associated manufacturing processes. Previously, Dr. Plavsic was in charge of gene therapy development at Genzyme, overseeing the upstream, downstream, formulation and analytical developments of viral vectors used in gene therapy applications. Before Genzyme, he held various senior leadership positions with AstraZeneca, Q-One Biotech, and Life Technologies, Inc. Dr. Plavsic’s professional experience ranges from Europe, Australasia and USA, and his technical expertise spans across a wide spectrum of drug development and manufacturing activities, including critical animal origin raw materials, cell culture media, GMP QC testing, GLP non-clinical studies, process and analytical development, GMP manufacturing, contract manufacturing, and supply chain. Dr. Plavsic received his Ph.D. in Virology and Molecular Cell Biology, M.Sc. in Virology and Immunology, and Doctor of Veterinary Medicine (D.V.M.) degree from the University of Belgrade in Yugoslavia. He has a Board certification in Microbiology, subspeciality Virology, from the American College of Veterinary Microbiologists.
What is Mark Plavsic's net worth?
The estimated net worth of Mark Plavsic is at least $227,728.16 as of October 16th, 2024. Dr. Plavsic owns 121,132 shares of Fate Therapeutics stock worth more than $227,728 as of December 18th. This net worth approximation does not reflect any other investments that Dr. Plavsic may own. Learn More about Mark Plavsic's net worth.
How do I contact Mark Plavsic?
Has Mark Plavsic been buying or selling shares of Fate Therapeutics?
Mark Plavsic has not been actively trading shares of Fate Therapeutics during the past quarter. Most recently, Mark Plavsic sold 3,719 shares of the business's stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $24.61, for a transaction totalling $91,524.59. Following the completion of the sale, the insider now directly owns 127,123 shares of the company's stock, valued at $3,128,497.03. Learn More on Mark Plavsic's trading history.
Who are Fate Therapeutics' active insiders?
Are insiders buying or selling shares of Fate Therapeutics?
In the last year, Fate Therapeutics insiders bought shares 1 times. They purchased a total of 44,630 shares worth more than $166,023.60. In the last year, insiders at the biopharmaceutical company sold shares 6 times. They sold a total of 46,046 shares worth more than $202,409.98. The most recent insider tranaction occured on August, 6th when Director Yuan Xu sold 633 shares worth more than $2,677.59. Insiders at Fate Therapeutics own 5.0% of the company.
Learn More about insider trades at Fate Therapeutics. Information on this page was last updated on 8/6/2024.